Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.17 +1.93%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
